Stefan Galluppi

About Stefan Galluppi

Stefan Galluppi, 38, is LifeMD’s Chief Innovation Officer; he has served as Chief Innovation & Marketing Officer since December 2020 after prior roles as CTO (2016–2020) and COO (Mar 2019–Nov 2020) . He brings 10+ years of experience building technology platforms for direct‑to‑consumer marketing; previously CTO at Runaway Products, a DRTV-focused firm . Company performance context during his executive tenure includes telehealth revenue up 18% year-over-year in Q3 2025 and telehealth adjusted EBITDA up 30% year-over-year; consolidated Q3 2025 revenue grew 13% to $60.2M with adjusted EBITDA of $5.1M . Company TSR improved from $29.71 at end-2022 to $105.61 at end-2023, then was $63.06 at end-2024 (fixed $100 benchmark), while net losses narrowed versus prior years .

Past Roles

Organization	Role	Years	Strategic Impact
LifeMD	Chief Technology Officer	2016–2020	Built and optimized tech systems to scale DTC campaigns
LifeMD	Chief Operating Officer	Mar 2019–Nov 2020	Operations leadership during scaling
LifeMD	Chief Innovation & Marketing Officer (then Chief Innovation Officer)	Dec 2020–present	Led innovation/marketing across telehealth platform
LifeMD Board	Director	2017–2018; re-appointed 2018; resigned 2023	Board-level input during legacy business transition

External Roles

Organization	Role	Years	Strategic Impact
Runaway Products	Chief Technology Officer	Prior to LifeMD (years not disclosed)	Built and optimized systems to scale DRTV campaigns for efficiency and profitability

Fixed Compensation

Year	Base Salary ($)	Target Bonus ($)	Actual Bonus Paid ($)
2023	300,000	100,000	275,000

Notes:

Employment term is indefinite; base salary set at $300,000 with $100,000 target bonus under the Galluppi Employment Agreement (Second Amendment 11/15/2021; Fourth Amendment 10/12/2023) .

Performance Compensation

Equity Awards

Grant Type	Grant Date	Shares/Units	Vesting	Performance Linkage
Restricted Shares	Oct 12, 2023	90,000	30,000 vested Jan 1, 2024; 60,000 vest Jan 1, 2025	Time-based
Performance Restricted Shares	Oct 12, 2023	60,000	Vests based on personal performance over a two-year period	Personal performance goals (not disclosed)
Conditional Shares (subject to availability under plan)	No later than Oct 12, 2024	150,000	Grant contingent on share availability; vesting terms not disclosed	Not disclosed

Company Bonus Program Structure (2024 reference for alignment)

Metric	Weight	Target	2024 Actual	Payout as % of Target
Telehealth Net Revenue	30%	$135–$145M	$158.4M	200%
Telehealth Cash Rebilling Revenue	30%	$100–$108M	$119.8M	200%
Telehealth Adjusted EBITDA	40%	$0–$7M	$7.4M	100%
Total	100%	—	—	160%

Notes:

2024 payouts listed were for the NEOs that year (Schreiber, Wijnker, Biffar); Galluppi was an NEO in 2023 (received $275,000 bonus), but 2024 NEOs did not include him .

Equity Ownership & Alignment

Item	Detail
Total Beneficial Ownership	1,717,249 shares (4.20% of 40,888,346 outstanding as of Apr 24, 2024)
Ownership Breakdown	1,644,800 shares via American Nutra Tech, LLC; 72,449 shares directly; sole voting/dispositive power over American Nutra Tech holdings
Outstanding Awards (as of Dec 31, 2023)	90,000 unvested restricted shares ($746,100 MV at $8.29); 60,000 unearned performance shares ($497,400 MV at $8.29)
Hedging/Pledging	Company prohibits hedging transactions by directors/officers/employees; pledging not disclosed
Options	No options disclosed for Galluppi; Company stated it does not currently grant options
Ownership Guidelines	Not disclosed

Employment Terms

Term	Key Provisions
Agreement & Term	Indefinite term; Galluppi Employment Agreement with Second Amendment (11/15/2021) and Fourth Amendment (10/12/2023)
Compensation	Base salary $300,000; target bonus $100,000
Equity	90,000 RS; 60,000 performance RS; conditional 150,000 shares (subject to plan availability)
Severance	Not disclosed in proxy for Galluppi
Change-of-Control	Plan-level single-trigger: all unvested restricted stock and RSUs vest 100% upon a Sale Event; company may cash-out awards at Sale Price
Clawback	Compensation Committee administers incentive compensation recovery policy
Benefits	Participation in 401(k) plan with company matching; matching contributions fully vest by 2nd anniversary of hire date

Performance & Track Record

Role impact: Led innovation/marketing and platform optimization; prior technology leadership building scalable DTC systems .
Company KPIs context: Q3 2025 telehealth revenue +18% y/y; telehealth adjusted EBITDA +30% y/y; consolidated revenue $60.2M with adjusted EBITDA $5.1M; telehealth subscribers >310,000 at quarter end .
TSR trajectory: $29.71 (end‑2022), $105.61 (end‑2023), $63.06 (end‑2024) (fixed $100 benchmark), with net losses narrowing vs prior years .

Investment Implications

Alignment: Significant equity stake (4.20%) and substantial time/performance‑linked share awards tie Galluppi’s incentives to shareholder outcomes; anti‑hedging policy strengthens alignment; no pledging disclosed .
Vesting/Selling Pressure: Time‑based RS grants vesting on fixed dates (30k on 1/1/2024; 60k on 1/1/2025) may create periodic supply; performance RS (60k) introduces execution‑based upside/downside (specific personal goals not disclosed) .
Change‑of‑Control Economics: Plan’s single‑trigger acceleration of unvested awards upon a Sale Event can amplify realized compensation in transactions, potentially affecting perceived deal incentives .
Retention Risk: Indefinite term without disclosed severance suggests retention relies on equity/bonus rather than contractual severance; meaningful equity ownership and ongoing equity grants support retention .
Company Performance Tailwinds/Risks: Telehealth growth, pharmacy integration, and product expansions noted by management support medium‑term value creation; TSR variability underscores market risk; litigation and control environment noted in filings are broader company considerations (not specific to Galluppi) .

Data sources: LifeMD DEF 14A (Apr 29, 2024; Apr 28, 2025), Q3 2025 earnings call transcript (Nov 17, 2025).